Catalog No.: PC-24932Not For Human Use, Lab Use Only.
Acevaltrate is a novel ferroptosis inducer and dual inhibitor of PCBP1/2 and GPX4, also inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively.
Acevaltrate is a novel ferroptosis inducer and dual inhibitor of PCBP1/2 and GPX4, also inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively. Acevaltrate promotes apoptosis and inhibits proliferation by suppressing HIF-1alpha accumulation in cancer cells. Acevaltrate not only increases Fe2+ levels in colorectal cancer cells by targeting iron chaperones PCBP1/2 and reducing their expression but also disrupts the antioxidant system of colorectal cancer cells by targeting GPX4 and inhibiting its enzymatic activity, leading to its ubiquitin-mediated degradation. Acevaltrate overcomes myeloma resistance to bortezomib via pyroptosis by promoting BAX translocalization to mitochondria.
